Since 2000 we have performed 54 HSCT procedures (on 44 children) for MPSIH at Manchester (Table 1). Of these, six (13.6 %) displayed significant cardiomyopathy at presentation. Interestingly three of these were from the same extended pedigree (from Kuwait), sharing the R628X IDUA gene mutation. All children were diagnosed within the first 4 months of life with dilated cardiomyopathy and significant LV functional impairment. Symptomatic cardiac failure was the predominant presenting feature in five children, with silent cardiomyopathy identified on screening echocardiography in the other. Median FS and EF at diagnosis were 12.5 % (range 3–20 %) and 35 % (15–40 %) respectively. Electrocardiography (ECG) patterns varied, but included strikingly tall QRS complexes consistent with LV enlargement/hypertrophy and evidence of myocardial ischaemia (ST segment depression; T wave inversion) in several cases. Further detailed cardiac investigation (including serum troponin) was rarely performed.
Case#: Patients 2 (male), 4 (male), and 5 (female). Kuwait. Onset between 1wk-3mo.
DiseaseAssertion: MPS I Hurler
FamilyInfo: Patients are from the same extended pedigree (family in Kuwait)
CasePresentingHPOs: α-L-iduronidase activity= 3.73 umol/g/hr (normal range 10–50) after commencing ERT. ERT for 9 wks. Congestive cardiac failure. LV fractional shortening=10%. LV ejection fraction=29%. HSCT at 17mo. α-L-iduronidase activity= 11.24 umol/g/hr (normal range 10–50) at follow up. GAG= 31.3 after transplant. Enzyme replacement therapy results in a significant reduction in urine GAGs (either total or heparan sulfate)
CaseHPOFreeText:
CaseNotHPOs:
CaseNotHPOFreeText:
GenotypingMethod:
PreviouslyPublished: n/a
Variant: Arg628Ter homozygous. Proband was homozygous for this variant. 0 points (maximum for homozygous cases has already been reached)
ClinVar: 550421
CAID: CA2802462
SupplementalData: n/a